Diabetes Update: Your Guide to the Latest ADA Standards by Johnson, Eric et al.
Touro Scholar 
College of Osteopathic Medicine (TUC) 
Publications and Research College of Osteopathic Medicine 
2016 
Diabetes Update: Your Guide to the Latest ADA Standards 
Eric Johnson 
Florence Warren 
Neil Skolnik 
Jay H. Shubrook 
Touro University California, jay.shubrook@tu.edu 
Follow this and additional works at: https://touroscholar.touro.edu/tuccom_pubs 
 Part of the Endocrine System Diseases Commons, and the Nutritional and Metabolic Diseases 
Commons 
Recommended Citation 
Johnson, E., Warren, F., Skolnik, N., & Shubrook, J. H. (2016). Diabetes update: Your guide to the latest 
ADA standards. Journal of Family Practice, 65(5), 310-318. 
310
Eric Johnson, MD; 
Florence Warren, DO; 
Neil Skolnik, MD;  
Jay H. Shubrook, DO
Altru Diabetes Center, 
Grand Forks, ND 
(Dr. Johnson); Abington-
Jefferson Health, Abington, 
Pa (Dr. Warren); Temple 
University School of  
Medicine, Philadelphia, Pa 
(Dr. Skolnik); Touro 
University, Vallejo, Calif 
(Dr. Shubrook)
  jay.shubrook@tu.edu
Dr. Johnson serves on the Novo 
Nordisk Speakers’ Bureau and 
on an advisory panel for Sanofi. 
Dr. Skolnik serves on the Astra-
Zeneca Speakers’ Bureau and 
has served on advisory panels 
for AstraZeneca, Boehringer 
Ingelheim, Eli Lilly and Company, 
Novartis, Sanofi, and Teva. Dr. 
Shubrook has received research 
support from Sanofi and served 
as a consultant to Eli Lilly and 
Company, Novo Nordisk, Astra-
Zeneca, and GlaxoSmithKline. 
Dr. Warren reported no potential 
conflict of interest relevant to 
this article.
Diabetes update: Your guide 
to the latest ADA standards 
The authors highlight the latest changes in the ADA 
standards and review recommendations of particular 
relevance for family physicians. 
Prevention of diabetes, as well as early detection and treatment of both pre-diabetes and diabetes, is critical to 
the health of our country.  Because evidence-
based guidelines are key to our ability to 
effectively address the nation’s diabetes epi-
demic, the American Diabetes Association 
(ADA) updates its “Standards of Medical Care 
in Diabetes” annually to incorporate new evi-
dence or clarifications.
The 2016 standards,1 available at pro-
fessional.diabetes.org/jfp, are a valuable 
resource. Among the latest revisions: an ex-
pansion in screening recommendations, a 
change in the age at which aspirin therapy for 
women should be considered, and a change in 
A1C goals for pregnant women with diabetes. 
As members of the ADA’s primary care 
advisory group, we use a question and an-
swer format in the summary that follows to 
highlight recent revisions and review other 
recommendations that are of particular rel-
evance to physicians in primary care. It is 
important to note, however, that ADA rec-
ommendations are not intended to preclude 
clinical judgment and should be applied in 
the context of excellent medical care.
Diagnosis and screening 
Have the 2016 ADA standards changed 
the way diabetes is diagnosed? 
No. The criteria for a diagnosis of diabetes 
did not change. Diabetes and prediabetes 
are still screened for and diagnosed with 
any of the following: a fasting plasma glu-
cose (FPG); a 2-hour 75-g oral glucose toler-
ance test (OGTT); a random plasma glucose 
>200 mg/dL with symptoms of hyperglycemia; 
or A1C criteria (TABLE 1).1,2 The wording was 
changed, however, to make it clear that no one 
test is preferred over another for diagnosis.  
Have screening recommendations 
been revised?
Yes. In addition to screening asymptomatic 
adults of any age who are overweight or obese 
and have one or more additional risk factors 
for diabetes, the 2016 standards recommend 
screening all adults 45 years and older, re-
gardless of weight.
Is an A1C <7% the recommended  
treatment goal for everyone with diabetes?
No. An A1C <7% is considered reasonable for 
most, but not all, nonpregnant adults. In the 
last few years, the ADA has focused more on 
individualized targets. 
Tighter control (<6.5%)—which is asso-
ciated with lower rates of eye disease, kidney 
disease, and nerve damage—may be appro-
priate for patients who have no significant 
hypoglycemia, no cardiovascular disease 
(CVD), a shorter duration of diabetes, or a 
longer expected lifespan.
Conversely, a higher target (<8%) may be 
appropriate for patients who are older, have 
longstanding diabetes, advanced macrovascu-
lar or microvascular disease, established com-
plications, or a limited life expectancy.3,4 
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❚ Pregnancy. The 2016 standards have 
a new target for pregnant women with dia-
betes: The ADA previously recommended 
an A1C <6% for this patient population, but 
now recommends a target A1C between 6% 
and 6.5%. This may be tightened or relaxed, 
however, depending on individual risk of 
hypoglycemia. 
In focusing on individualized targets and 
hypoglycemia avoidance, the ADA notes that 
attention must be paid to fasting, pre-meal, 
and post-meal blood glucose levels to achieve 
treatment goals. The 2016 standards em-
phasize the importance of patient-centered 
diabetes care, aligned with a coordinated, 
team-based chronic care model. 
Diabetes self-management education and 
support is indicated for those who are newly di-
agnosed, and should be provided periodically 
based on glucose control and progression of 
the disease. All patients should receive educa-
tion on hypoglycemia risk and treatment.
Prediabetes and prevention  
What is prediabetes and what can I do 
to prevent patients with prediabetes 
from developing diabetes?
Patients with impaired glucose tolerance, 
impaired fasting glucose, or an A1C between 
5.7% and 6.4% are considered to have pre-
diabetes and are at risk for developing type 2 
diabetes. 
Family physicians should refer patients 
with prediabetes to intensive diet, physi-
cal activity, and behavioral counseling pro-
grams like those based on the Diabetes 
Prevention Program study (www.niddk.nih.
gov/about-niddk/research-areas/diabetes/
diabetes-prevention-program-dpp/Pages/ 
default.aspx). Goals should include a minimum 
7% weight loss and moderate-intensity physi-
cal activity, such as brisk walking, for at least 
150 minutes per week.
Lifestyle modification programs have 
been shown to be very effective in prevent-
ing diabetes, with about a 58% reduction in 
the risk of developing type 2 diabetes after 
3 years.5 The 2016 standards added a recom-
mendation that physicians encourage the use 
of new technology, such as text messaging or 
smart phone apps, to support such efforts. 
Should I consider initiating oral  
antiglycemics in patients with prediabetes?
Yes. Pharmacologic agents, including metfor-
min, acarbose, and pioglitazone, have been 
shown to decrease progression from predia-
The latest ADA revisions 
include an expansion  
in screening  
recommendations and 
changes in the age  
at which aspirin therapy 
for women should be  
considered and in A1C 
goals for pregnant 
women with diabetes.
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For patients 
with diabetes, 
a sustained 
weight loss  
of 5% may  
improve  
glycemic control 
and reduce  
the need 
for medication. 
betes to type 2 diabetes. Thus, antiglycemics 
should be considered for certain patients. Met-
formin is especially appropriate for women 
with a history of gestational diabetes, patients 
who are younger than 60 years, and those who 
have a body mass index (BMI) ≥35 kg/m2.6 
How often should I screen patients 
with prediabetes?
Patients with prediabetes should be screened 
annually. Such individuals should also be 
screened and treated for modifiable cardio-
vascular risk factors. There is strong evidence 
that the treatment of obesity can be ben-
eficial for those at any stage of the diabetes 
spectrum. 
Obesity management  
What do the 2016 ADA standards  
recommend for obese patients 
with diabetes?
With more than two-thirds of Americans ei-
ther overweight or obese, the ADA added 
a new section on obesity management and 
calls on health care providers to:  
• weigh patients and calculate and doc-
ument their BMI at every visit, and
• counsel those who are overweight or 
obese on the benefits of even modest 
weight loss. 
The ADA recommends a sustained 
weight loss of 5%, which can improve glyce-
mic control and reduce the need for diabetes 
medications,7-9 although weight loss of ≥7% 
is optimal. Physicians are also called on to 
assess each patient’s readiness to engage in 
therapeutic lifestyle change to maintain a 
modest weight loss.
Treatment for obesity can include thera-
peutic lifestyle change (reduction in calories, 
increase in physical activity) and behavioral 
therapy. For refractory patients, pharmaco-
logic therapy and bariatric surgery may be 
considered. 
Interventions should be high-intensity 
(≥16 sessions in 6 months) and focus on diet, 
physical activity, and behavioral strategies to 
achieve a 500 to 750 calorie deficit per day.10 
Long-term (≥1 year) comprehensive weight 
maintenance programs should be prescribed 
for those who achieve short-term weight 
loss.11,12 Such programs should provide at 
least monthly contact and encourage ongoing 
monitoring of body weight (weekly or more 
frequently), continued consumption of a re-
duced-calorie diet, and participation in high 
levels of physical activity (200 to 300 minutes 
per week). 
Glycemic treatment  
What are some of the key factors  
that distinguish the different type 2  
diabetes medications from one another?  
An increasing understanding of diabetes 
pathophysiology has led to a wider array of 
medications, making treatment more com-
plex than ever. It is important for physicians 
to have a strong working knowledge of the 
various classes of antidiabetic agents and the 
subtleties between drugs in the same class to 
best individualize treatment.
Here are the highlights of each class 
of medication listed in the ADA/European 
TABLE 1 
Criteria for the diagnosis of prediabetes and diabetes1,2
Prediabetes Diabetes
A1C 5.7%-6.4% ≥6.5%*
FPG 100-125 mg/dL (5.6-6.9 mmol/L) ≥126 mg/dL (7 mmol/L)*
OGTT 140-199 mg/dL (7.8-11 mmol/L) ≥200 mg/dL (11.1 mmol/L)*
RPG ≥200 mg/dL (11.1 mmol/L)**
FPG, fasting plasma glucose; OGTT, oral glucose tolerance test; RPG, random plasma glucose. 
 *In the absence of unequivocal hyperglycemia, results should be confirmed by repeating the test.
**Random plasma glucose is diagnostic only in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis.
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Patients who  
fail to achieve  
or maintain their 
A1C goal after 
one year may 
need to begin 
insulin therapy. 
Association for the Study of Diabetes algo-
rithm for the management of type 2 dia-
betes,13  which is available at http://care.
diabetesjournals.org/content/38/1/140/
F2.large.jpg): 
❚ Metformin is the preferred initial med-
ication for all patients who can tolerate it and 
have no contraindications. The drug is cost- 
effective, weight neutral, and has had posi-
tive cardiovascular and mortality outcomes 
in long-term studies. Adverse gastrointestinal 
(GI) effects, including nausea, diarrhea, and 
dyspepsia, are common but can be reduced 
with a slow titration of the drug. Metformin 
should be used with caution in those with re-
nal disease. The dose should be reduced if the 
estimated glomerular filtration rate (eGFR) 
<45 mL/min/1.73m2 and the drug discontin-
ued if eGFR <30 mL/min/1.73 m2.
❚ Sulfonylureas/meglitinides stimulate 
insulin secretion in a glucose-independent 
manner. They are cost-effective and have 
high efficacy early in the disease and with 
initial use, but the effect wanes as the dis-
ease progresses. This class of drugs is asso-
ciated with weight gain and hypoglycemia. 
Second-generation sulfonylureas (glipizide, 
glimepiride) are recommended; meglitinides 
are more expensive than sulfonylureas.
❚ Thiazolidinediones work to improve 
insulin sensitivity in the periphery and have 
a low risk of hypoglycemia. They have been 
associated with fluid retention, weight gain, 
and worsening of pre-existing congestive 
heart failure, but previous cardiovascular 
concerns (with rosiglitazone)14 and blad-
der cancer risks (with pioglitazone)15-17 have 
been refuted. Thiazolidinediones are contra-
indicated in those with Class III and IV con-
gestive heart failure, however, and patients 
taking them require careful monitoring for 
weight gain, fluid retention, and exacerbation 
of heart failure.
❚ Dipeptidyl peptidase-4 inhibitors 
(DPP4Is) work to reduce the breakdown of 
endogenous incretin hormones. These oral 
agents increase insulin secretion in a glu-
cose-dependent manner; more insulin is se-
creted when glucose is higher and less when 
glucose is closer to normal. This means that 
there is a much lower risk of hypoglycemia 
when a DPP4I is used as monotherapy. 
❚ Glucagon-like peptide 1 receptor 
agonists (GLP-1RAs), which are injectable, 
also work via incretin hormones and stimu-
late insulin in a glucose-dependent manner. 
They are associated with weight loss and low 
rates of hypoglycemia. Adverse GI effects are 
common with this class of drugs, but can 
be reduced by titrating the medication and 
avoiding overeating.  GLP-1RAs can be taken 
twice daily to once weekly, depending on the 
specific agent. 
❚ Sodium glucose transporter 2 inhibi-
tors (SGLT2Is) are oral agents and the newest 
class of antidiabetes drugs. The drugs help 
block the reabsorption of glucose, thereby 
lowering glucose levels, blood pressure, and 
weight in many patients. The most common 
adverse effects are urinary tract and genital 
yeast infections. SGLT2Is should not be giv-
en to patients with advanced renal disease 
(chronic kidney disease Stages 3B-5) because 
they will not be effectively absorbed. 
The US Food and Drug Administration 
(FDA) recently issued a warning about the risk 
of ketoacidosis with these agents,18 and pa-
tients should be advised to stop taking them 
and to seek immediate medical attention if 
they develop symptoms of ketoacidosis, such 
as excessive thirst, frequent urination, nausea 
and vomiting, abdominal pain, weakness or 
fatigue, shortness of breath, fruity-scented 
breath, or confusion.
❚ Insulin is eventually needed by most 
patients with type 2 diabetes who live long 
enough to see the disease progress. The most 
common adverse effects are weight gain and 
hypoglycemia. There are many types of in-
sulin, but only one that is delivered via in-
halation—human insulin inhaled powder. 
Inhaled insulin, however, has the potential 
for adverse pulmonary effects, including 
cough and reduction of peak expiratory flow. 
Therefore, pulmonary function testing is rec-
ommended prior to its use.
Treatment goal attainment should be 
evaluated every 3 months, and treatment ti-
trated at 3-month intervals if goals are not 
achieved. The ADA/European Association 
for the Study of Diabetes’ algorithm indicates 
that patients are likely to need insulin a year 
after diagnosis if their A1C goal has not been 
achieved or maintained.13 
CONTINUED
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Patients  
≥40 years will 
need moderate- 
to high-intensity 
statin therapy 
to lower their 
atherosclerotic 
cardiovascular 
disease risk.
The following medications are not in-
cluded in the algorithm but are included in 
the 2016 standards, and may be helpful for 
certain patients:
❚ Alpha-glucosidase inhibitors delay the 
absorption of glucose from the proximal to 
distal GI tract, thereby reducing postprandial 
hyperglycemia. Flatulence and leakage of 
stool—the most common adverse effects—
have limited their use in the United States.  
❚ Bile acid sequestrants (colesevelam) 
treat both hyperlipidemia and diabetes. 
The medications work by reducing glucose 
absorption from the GI tract. They reduce 
postprandial hyperglycemia, with a low risk 
of hypoglycemia. Colesevelam’s use is lim-
ited, however, because of the number of pills 
needed (6 daily).
❚ Bromocriptine affects satiety levels 
via the central nervous system, and is avail-
able in a specific formulation for the treat-
ment of diabetes. “First-dose” hypotension, 
however, is an adverse effect of considerable 
concern.1
❚ Pramlintide, an injectable amylin mi-
metic given to patients on prandial insulin, 
can reduce postprandial glucose levels. The 
most common adverse effects are upper GI 
symptoms and hypoglycemia. Due to the ad-
verse effects and the need for an injection with 
each meal, pramlintide is used infrequently.
Cardiovascular risk reduction
Has the ADA revised its recommendations 
for cardiovascular disease risk  
management?
Yes. There have been several changes. The 
first is in terminology, with atherosclerotic 
cardiovascular disease (ASCVD) replac-
ing CVD alone. While new recommenda-
tions for statin therapy for adults older than 
40 years (TABLE 2)1 were also added, the em-
phasis remains on therapeutic lifestyle change 
as an effective treatment for hypertension. 
These modifications should include at least 
150 minutes of moderate physical activity per 
week and, for most patients, a reduction in 
total calories, saturated fat, and sodium. 
It is important to remind patients that 
to maximize the benefits in terms of treating 
hyperglycemia, hypertension, and dyslipid-
emia, such changes must be maintained over 
the long term. 
❚ Aspirin therapy. The ADA also revised 
its recommendation regarding aspirin thera-
py. Based on new evidence in the treatment 
of women with ASCVD risk, the standards 
now call for considering aspirin therapy 
(75-162 mg/d) in both women and men 
≥50 years as a primary prevention strategy 
for those with type 1 or type 2 diabetes with 
a 10-year ASCVD risk of >10%.  (The previous 
standards recommended this only for wom-
en older than 60 years.)   
Antiplatelet therapy is now recommend-
ed for patients younger than 50 years with 
multiple risk factors, and as secondary pre-
vention in those with a history of ASCVD.19-21  
❚ Hypertension. The ADA’s recommen-
dations for treating hypertension in patients 
with diabetes have not changed; the goal re-
mains <140/<90 mm Hg. Lower targets may 
be appropriate for younger patients, those 
with albuminuria, and individuals with ad-
ditional CVD risk factors; however, systolic 
pressure <130 mm Hg has not been shown 
to reduce CVD outcomes, and diastolic pres-
sure <70 mm Hg has been associated with 
higher mortality.22 
Optimal medication and lifestyle therapy 
are important to achieve goals, with avoid-
ance of undue treatment burden. Angioten-
sin converting enzyme (ACE) inhibitors or 
angiotensin receptor blockers (ARBs), but not 
both, should be included as part of treatment. 
Other agents, such as a thiazide diuretic, may 
be needed to achieve individual goals. Se-
rum creatinine/eGFR and serum potassium 
levels should be monitored with the use of 
diuretics.  
❚ Lipids. The 2016 standards include no-
table changes in lipid management. The ADA 
sees a role for ezetimibe for select patients, 
based on studies such as the IMPROVE IT 
trial23 that included participants with diabe-
tes. The ADA also added a table highlighting 
statin recommendations and delineating high 
and moderate-intensity statins (TABLE 3).1 
Those younger than 40 years with no other 
risk factors may not need a statin, but pa-
tients ages 40 or older will need moderate- 
to high-intensity statin therapy to effectively 
lower ASCVD risk.24-28 
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The ADA  
sees a role  
for ezetimibe  
for select  
patients, based 
on studies 
such as the 
IMPROVE IT trial 
that included  
participants  
with diabetes.
These recommendations reflect a com-
prehensive plan to reduce ASCVD in this at-
risk population, which should also include 
lifestyle modification, including smoking 
prevention and quit strategies, as needed.  
Microvascular complications
› DIABETIC KIDNEY DISEASE
How should I diagnose nephropathy? 
The ADA changed the terminology, referring 
to “diabetic kidney disease” (DKD) rather 
than nephropathy to highlight the fact that 
the focus is on kidney disease directly linked 
to diabetes. 
Other recommendations include an 
annual assessment of urinary albumin (eg, 
spot urine albumin-to-creatinine ratio and 
eGFR) for patients who have had type 1 dia-
betes for ≥5 years and all patients who have 
type 2 diabetes. Two out of 3 abnormal spec-
imens collected within a 3- to 6-month pe-
riod indicate the presence of albuminuria. 
What can be done to prevent or slow 
the progression of DKD? 
Optimal BP and glycemic control are key,29-35 
along with diet and medication. For patients 
with DKD, dietary protein intake should be 
0.8 g/kg body weight per day. ACE inhibi-
tors and ARBs have been shown to slow the 
decline in eGFR in patients with elevated uri-
nary albumin excretion (>30 mg/day). 
However, neither an ACE inhibitor nor 
an ARB is recommended for the primary pre-
vention of DKD in patients who have normal 
BP, normal urine albumin-to-creatinine ratio 
(<30 mg/g), and normal eGFR. In addition, 
combined use of an ACE inhibitor and an 
ARB should be avoided, as it provides no ad-
ditional benefit and increases the risk of ad-
verse effects.29
› RETINOPATHY 
How should I manage retinopathy  
in patients with diabetes?
As with the management of DKD, it is im-
portant to optimize glycemic and BP control 
to reduce the risk, or slow the progression, 
of retinopathy. Intensive diabetes man-
agement, with the goal of achieving near-
normal glycemic levels, has been shown 
in large prospective randomized studies to 
prevent or delay the onset and progression 
TABLE 2
Statin (or combination) therapy for which patients?1
Age Risk factors Recommended statin intensity* 
<40 years None None
ASCVD risk factor(s)† Moderate or high
ASCVD High
40–75 years None Moderate
ASCVD risk factors High
ASCVD High
ACS and LDL >50 mg/dL in an individual 
who can’t tolerate high-dose statin
Moderate + ezetimibe
>75 years None Moderate
ASCVD risk factors Moderate or high
ASCVD High
ACS and LDL >50 mg/dL in an individual 
who can’t tolerate high-intensity statin
Moderate + ezetimibe
ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; LDL, low-density lipoprotein. 
*In addition to lifestyle therapy.
†Risk factors include LDL cholesterol ≥100 mg/dL, high blood pressure, smoking, overweight or obesity, and a family history  
of premature ASCVD.
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The presence  
of retinopathy 
is not a  
contraindication 
to aspirin  
therapy for 
atherosclerotic 
cardiovascular 
disease  
prevention,  
as aspirin does 
not increase the 
risk of retinal 
hemorrhage.
of diabetic retinopathy.33,36 The presence 
of retinopathy is not a contraindication to 
aspirin therapy for ASCVD prevention, as 
aspirin does not increase the risk of retinal 
hemorrhage.
When should patients with diabetes  
be screened for retinopathy? 
Patients with type 1 diabetes should have an 
initial dilated and comprehensive eye ex-
amination by an ophthalmologist or optom-
etrist within 5 years of the onset of diabetes. 
Those with type 2 diabetes should have such 
an exam shortly after diagnosis. The exam 
should be repeated annually; if there is no 
evidence of retinopathy, however, 2-year in-
tervals may be considered. 
› PERIPHERAL NEUROPATHY
When and how should I screen patients 
with diabetes for neuropathy?
All patients should be screened for diabetic 
peripheral neuropathy (DPN) starting at di-
agnosis of type 2 diabetes and 5 years after 
the diagnosis of type 1 diabetes, and contin-
ued at least annually thereafter. Assessment 
should include a detailed history and 10-g 
monofilament testing, as well as at least one 
of the following tests: pinprick, temperature, 
and vibration sensation.
It is important, too, to screen patients 
with more advanced diabetes for signs and 
symptoms of autonomic neuropathy. Signs 
and symptoms may include resting tachy-
cardia, exercise intolerance, orthostatic 
hypotension, gastroparesis, constipation, 
impaired neurovascular function, and auto-
nomic failure in response to hypoglycemia. 
In men, diabetic autonomic neuropathy may 
cause erectile dysfunction and/or retrograde 
ejaculation.
How should I manage patients  
who have DPN?
Tight glycemic control is the only measure 
that has been shown to prevent or delay 
the development of DPN or cardiac auto-
nomic neuropathy in patients with type 1 
diabetes,37,38 and to slow the progression 
of neuropathy in some patients with type 2 
diabetes.39
The FDA has approved pregabalin, du-
loxetine, and tapentadol for the treatment 
of pain associated with DPN. Tricyclic anti-
depressants, gabapentin, venlafaxine, carba-
mazepine, tramadol, and topical capsaicin, 
although not approved for the treatment of 
painful DPN, may also be effective in treating 
neuropathic pain. 
For those with autonomic neuropathy, 
dietary changes and prokinetic agents such 
as erythromycin may alleviate gastroparesis. 
Due to extrapyramidal adverse effects, meto-
clopramide is reserved for the most severe 
and unresponsive cases. Recurrent urinary 
tract infections, pyelonephritis, inconti-
nence, or palpable bladder should prompt 
an evaluation for bladder dysfunction. Con-
trolling lipids and BP, quitting smoking, and 
making other lifestyle changes can reduce 
both the development and the progression of 
autonomic neuropathy. 
› FOOT CARE/PERIPHERAL ARTERIAL 
DISEASE 
What does the ADA recommend regarding 
foot care for patients with diabetes? 
The ADA’s standards recommend an annual 
comprehensive foot examination to identify 
risk factors predictive of ulcers and potential 
amputations. The exam should start with in-
spection and assessment of foot pulses and 
should seek to identify loss of peripheral 
TABLE 3
Statin drugs and daily dosage1
Moderate intensity (lowers LDL by 30% 
to <50%):
Atorvastatin 10-20 mg
Fluvastatin XL  80 mg
Lovastatin  40 mg
Pitavastatin  2-4 mg
Pravastatin  40-80 mg
Rosuvastatin  5-10 mg
Simvastatin  20-40 mg
High intensity (lowers LDL by ≥50%):
Atorvastatin  40-80 mg
Rosuvastatin  5-10 mg
LDL, low-density lipoprotein.
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The ADA also 
recommends 
that patients 
ages 19 to 
59 years receive 
the hepatitis B 
vaccine if they 
haven't already 
done so and that 
the vaccine be 
considered for 
those ≥60 years, 
as well.
sensation. The examination should include 
inspection of the skin, assessment of foot 
deformities, neurologic assessment includ-
ing 10-g monofilament testing and pinprick 
or vibration testing or assessment of ankle 
reflexes, and vascular assessment, including 
pulses in the legs and feet.40 
It is also important to screen patients for 
peripheral arterial disease (PAD), with a com-
prehensive medical history and physical exam 
of pulses. Ankle-brachial index testing (ABI) 
should be performed in patients with signs or 
symptoms of PAD, including claudication or 
skin and hair changes in the lower extremities. 
ABI may be considered for all patients with di-
abetes starting at age 50 and in those younger 
than 50 years who have risk factors.41 
Which patients with diabetes 
are at higher risk for foot complications? 
The following are risk factors for foot com-
plications: previous amputation, prior foot 
ulcer, peripheral neuropathy, foot deformity, 
peripheral vascular disease, visual impair-
ment, peripheral neuropathy (especially if on 
dialysis), poor glycemic control, and smok-
ing. Patients with high-risk foot conditions 
should be educated about their risk and ap-
propriate management.
A well-fitted walking shoe that cushions 
the feet and redistributes pressure is one op-
tion to help patients. Patients with bony de-
formities may need extra wide or deep shoes 
and patients with more advanced disease 
may need custom-fitted shoes.
When should patients be referred 
to a foot specialist? 
Refer patients to a foot care specialist for 
ongoing preventive care and lifelong sur-
veillance if they smoke or have a history of 
lower-extremity complications, a loss of pro-
tective sensation, structural abnormalities, 
or PAD.
› IMMUNIZATION
Are there special immunization 
recommendations for people 
with diabetes?
No. Children and adults with diabetes should 
be vaccinated according to age-related rec-
ommendations for the general population, 
the standards state. The ADA also recom-
mends that patients ages 19 to 59 years re-
ceive the hepatitis B vaccine if they haven’t 
already done so and that the vaccine be 
considered for those ≥60 years, as well. This 
is in keeping with the Centers for Disease 
Control and Prevention’s recommendation 
that adults with any medical, occupational, 
or other risk factor be immunized against 
hepatitis B.42                             JFP 
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